SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak Co. is trending due to its ongoing transformation from a legacy print business into high-margin sectors like pharmaceuticals and advanced materials, with the community highlighting the imminent launch of its pharma division in 2025. Discussions also focus on the company's debt reduction plans using pension assets, potential trade policy tailwinds, and undervalued real estate holdings. Investors are closely watching for news and contracts related to Kodak's pharmaceutical ventures, with some speculating about partnerships and a potential meme stock resurgence.

COTI is a fast and light confidentiality layer on Ethereum. Powered by the breakthrough cryptographic protocol Garbled Circuits and secured by Ethereum, COTI introduces the most advanced and compliant solution for data protection on the public blockchain. Paving the way for the next wave of Web3 innovation and adoption, COTI unlocks a whole new world of use cases, including confidential transactions, Artificial Intelligence, DeFi, decentralized identification, and more.

COTI

COTI is trending as the community discusses its potential in the privacy and security sector, with comparisons being made to established coins like ZEC and its growing ecosystem. Bullish sentiment seems to be building, with some anticipating mainnet and new partnerships to serve as catalysts. Community members are also talking about accumulation and COTI's AI-driven trading potential.

The Filecoin network achieves staggering economies of scale by allowing anyone worldwide to participate as storage providers. It also makes storage resemble a commodity or utility by decoupling hard-drive space from additional services. On this robust global market the price of storage will be driven by supply and demand, not corporate pricing departments, and miners will compete on factors like reputation for reliability as well as price.

Filecoin

Filecoin is trending as investors discuss its potential in decentralized data storage, especially in light of AI and Web3 projects. Community members are actively comparing it to other cryptocurrencies like ZEC and DASH, speculating on price targets, and highlighting its real-world utility, such as competing with Amazon AWS. The conversation also mentions Filecoin's use cases with Solana and NASA.

Sei is a high-performance Layer 1 blockchain that scales the EVM with parallelized execution, enabling faster transactions, low fees, and seamless smart contract deployment. Sei removes traditional blockchain bottlenecks while maintaining full Ethereum compatibility. The upcoming Giga upgrade will deliver 50x improvements in EVM throughput, optimizing execution, consensus, and storage to push blockchain performance to web2 levels.

SEI is gaining attention as community members discuss its potential, comparing it to other popular chains like Solana and SUI. The recent listing on Robinhood is a catalyst, with some seeing it as a signal for potential growth, while others express concern about its historical impact on coin performance. Community discussions include speculation on future price targets and debate around whether it's a good entry point.

ArcelorMittal SA is a holding company, which engages in steelmaking and mining activities. It operates through the following business segments: NAFTA; Brazil; Europe; Africa and Commonwealth of Independent States (ACIS), and Mining. The NAFTA segment consists of flat products such as slabs, hot-rolled coil, cold-rolled coil, coated steel, and plate. The Brazil segment covers wire rod, bar and rebars, billets, blooms, and wire drawing. The Europe segment offers hot-rolled coil, cold-rolled coil, coated products, tinplate, plate, and slab. The ACIS segment produces a combination of flat, long, and tubular products. The Mining segment focuses on steel operations. The company was founded by Lakshmi Niwas Mittal in 1976 and is headquartered in Luxembourg.

ArcelorMittal - New York Shares - Level III

Arcelor Mittal

ArcelorMittal ($MT) is trending due to JPMorgan's recent upgrade to Overweight following reassuring Q3 results and a strong Q4 free cash flow outlook, sparking bullish sentiment. The community is discussing the potential for the stock to reach $50 and unusual options activity with call flow, while some remain skeptical due to the company's ownership structure and historical performance. Broader context includes discussions around materials sector corrections and potential new advancements in steelmaking with electric heating tech.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is trending as the community discusses its potential within the AI sector and recent price volatility. Some speculate on a bullish reversal and are loading up, while others point to Zcash potentially driving interest in NEAR. Discussions also mention staking options and cross-chain capabilities as potential catalysts.

Devon Energy Corp. engages in the exploration, development, and production of oil and natural gas properties. It develops and operates Delaware Basin, Eagle Ford, Heavy Oil, Barnett Shale, STACK, and Rockies Oil. The company was founded by J. Larry Nichols and John W. Nichols in 1971 and is headquartered in Oklahoma City, OK.

Devon Energy Corp.

Devon Energy is trending amid discussions of its recent earnings, with revenue exceeding expectations while earnings dipped year-over-year. Community members are weighing the sustainability of growth and anticipating the stock's potential to reach the $40 mark, while some express frustration with the stock's price movement relative to oil prices. Options activity is also being closely monitored.

Newsmax Inc. is a holding company, which engages in television broadcasting and multi-platform content publishing that produces original news and editorial content for consumers through various media outlets, including TV new channels, digital and print publications. It operates through the Broadcasting and Digital Segments. The Broadcasting segment produces and licenses news, business news and lifestyle content for distribution through both MVPDs and free OTT streaming platforms. The Digital segment is composed of Newsmax.com and affiliated websites. The company was founded by Christopher Ruddy in 1998 and is headquartered in Boca Raton, FL.

Newsmax Inc. - Ordinary Shares - Class B

Newsmax Inc

NMAX is trending due to options activity and speculation around its potential for high ROI, with traders discussing strategies involving January 2027 call options. The community is weighing positive catalysts, such as Newsmax's recent deal to make its channel available in numerous hotels, against concerns about dilution and the stock's overall performance. Broader market context includes its association with other Trump-related stocks and the media sector.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quant is seeing increased attention, with community members discussing its potential for significant gains and comparing it to other cryptocurrencies. Recent news and partnerships are fueling optimism, though some traders remain skeptical, pointing to past performance. Overall, the community is weighing the long-term potential of Quant against short-term market fluctuations.

Chewy, Inc. operates as an online retailer of pet food and other pet-related products and services. It supplies pet medications, food, treats and other pet-health products and services for dogs, cats, fish, birds, small pets, horses, and reptiles. It has a portfolio of pet healthcare offerings that includes Chewy Pharmacy, Connect with a Vet, and CarePlus, an exclusive suite of pet-first insurance and wellness plans. The company was founded by Ryan Cohen and Michael Day in September 2011 and is headquartered in Plantation, FL.

Chewy Inc - Ordinary Shares - Class A

Chewy Inc

Chewy ($CHWY) is trending as traders discuss its upcoming earnings and potential breakout, with some highlighting Mizuho's recent upgrade and a price target of $50. Bullish sentiment seems to be building due to strong Autoship sales and recurring revenue, even amid discussions of competition and market volatility. Some are speculating on a run to the $40-$50 range, while others are wary, citing past earnings disappointments and broader market concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance

Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying building a chip fab like TSMC's is "extremely hard."read more...

Pfizer Sweetens Offer For Metsera To $86.25/shr Amid Escalating Bidding War With Novo Nordisk

(RTTNews) - Metsera Inc. (MTSR) announced that it has entered into an amended merger agreement with Pfizer, under which Pfizer will acquire Metsera for up to $86.25 per share. The deal includes...

Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer

Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's...

Metsera (NASDAQ:MTSR) Trading Up 10.6% - Still a Buy?

Metsera (NASDAQ:MTSR) Trading 10.6% Higher - Here's What Happened...

Pfizer Discusses Drug Pricing Deal, Metsera Buyout Dispute on Q3 Call

Pfizer faces a fierce bidding war with Novo Nordisk over Metsera while securing a landmark U.S. drug pricing deal.

Investors Purchase High Volume of Put Options on Metsera (NASDAQ:MTSR)

Metsera Inc. (NASDAQ:MTSR - Get Free Report) was the recipient of unusually large options trading on Thursday. Stock traders purchased 2,401 put options on the company. This represents an increase of...

Tesla Investors Approve Musk Pay Package, Comcast's Sky in Talks to Buy ITV  The Opening Trade 11/7

Tesla shareholders approved a potential $1 trillion compensation package for Chief Executive Officer Elon Musk, the largest payout ever awarded to a corporate leader. Musk would have to meet certain...

<ul class="summary-bullets"><li>The details of the new bid could not be immediately ascertained, FT said.</li><li>Pfizer now has two days to match Novo’s bid or let its agreed-upon deal with Metsera fall through, the report stated.&nbsp;</li><li>Pfizer reportedly matched Novo’s last offer late on Wednesday, prompting Novo’s new bid.<br>&nbsp;</li></ul><p>Danish drugmaker Novo Nordisk has reportedly sweetened its bid further for obesity drug maker Metsera amid a rising bidding war with Pfizer.</p><p>The Financial Times<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/52216b29-9f22-4338-85a7-eacfc33103a1"> reported</a> on Thursday, citing people familiar with the matter, that Novo raised its bid after Pfizer matched its last offer, valuing the company at up to $10 billion, late on Wednesday.</p><p>The details of the new bid could not be immediately ascertained, FT said. Pfizer now has two days to match Novo’s bid or let its agreed-upon deal with Metsera fall through, the report stated.&nbsp;</p><h2 class="st-heading-2">Start Of The Bidding War</h2><p>Novo Nordisk first announced last week that it has submitted an unsolicited proposal to acquire Metsera, following Pfizer's agreement to acquire the smaller obesity biopharmaceutical company in September. Metsera determined that Novo’s bid was superior and gave Pfizer a certain number of days to negotiate the terms of their agreement. &nbsp;</p><p>On Monday, Metsera said that it has received revised bids from both Pfizer and Novo, valuing the company at up to $8.1 billion and $10 billion, respectively. Pfizer reportedly matched Novo’s offer late on Wednesday, prompting Novo’s new bid.</p><p>Pfizer had requested a temporary restraining order from the Delaware Chancery Court last week to prevent Metsera from terminating the existing merger agreement in favor of a competing proposal from Novo Nordisk. However, the court denied the request on Wednesday. Pfizer, however, said that it intends to pursue further litigation and expressed confidence in the merit of claims that Metsera has acted in breach of its contractual obligations. Metsera, on its side, dismissed Pfizer’s arguments as “nonsense.”</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p><a href="https://stocktwits.com/symbol/MTSR">MTSR stock</a> soared 14% at the time of writing. On Stocktwits, retail sentiment around MTSR stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.</p><p>MTSR stock has more than tripled this year.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/johnson-and-johnson-newly-acquired-antipsychotic-drug-approved-by-fda-for-major-depressive-disorder/cL2tuwZRERN">Johnson &amp; Johnson’s Newly Acquired Antipsychotic Drug Approved By FDA For Major Depressive Disorder</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

In this photo illustration, the Metsera logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Novo Nordisk Reportedly Refrains From Backing Down In Metsera Acquisition Battle, Sweetens Bid Further

According to an FT report, Pfizer now has two days to match Novo’s new bid or let its agreed-upon deal with Metsera fall through. 

Equity

<ul class="summary-bullets"><li>Delaware Chancery Judge Morgan Zurn ruled that Pfizer’s objections did not justify delaying Novo’s $10 billion acquisition of obesity-drug startup Metsera.</li><li>The court decision follows Metsera’s board reaffirming Novo’s revised $86.20-per-share offer as superior to Pfizer’s $8.1 billion counterproposal.</li><li>Pfizer vowed to continue its legal and antitrust challenges in Delaware federal court.</li></ul><p>Novo Nordisk’s U.S.-listed shares rose Wednesday, ending an 11-session losing streak, after a Delaware judge rejected Pfizer's request to block the Danish company’s $10 billion acquisition of obesity-drug startup Metsera Inc.</p><p>Delaware Chancery Judge Morgan Zurn said Pfizer’s objections didn’t warrant delaying the transaction and found no evidence Metsera’s board acted in bad faith when it labeled Novo’s offer “superior.” The ruling allows Novo to proceed with the deal, which topped Pfizer’s earlier $4.9 billion agreement announced in September, according to a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-11-05/pfizer-loses-legal-bid-to-temporarily-block-novo-s-metsera-offer">report</a>.</p><h2 class="st-heading-2"><strong>Revised Offers Raise The Stakes</strong></h2><p>On Tuesday, Metsera said it received a revised offer from Novo valuing the company at up to $86.20 per share, or about $10 billion. The new proposal includes $62.20 per share in cash, up from $56.50 in the original bid, plus contingent value rights worth up to $24.00 per share if certain milestones are achieved.</p><p>Pfizer also revised its terms, increasing upfront consideration to $60 per share and trimming the contingent payout to $10 per share, valuing its bid at roughly $8.1 billion. Despite the adjustment, Metsera’s board reaffirmed Novo’s offer as superior and gave Pfizer two business days to counter before terminating its merger agreement.</p><h2 class="st-heading-2"><strong>Pfizer Vows To Keep Fighting</strong></h2><p>Pfizer said the ruling “fails to address the legal issues raised” and vowed to continue litigation in Delaware federal court, calling Novo’s bid “an unprecedented and illegal scheme to circumvent antitrust scrutiny.” The company alleges Novo’s move is designed to protect its dominance in the GLP-1 obesity-drug space by neutralizing a future competitor.</p><p>Novo countered that the court’s ruling validates its approach and serves shareholders’ best interests. Its offer, which includes both upfront and milestone-based payments, aims to bring Metsera’s experimental weight-loss portfolio, which is a potential rival to Ozempic and Wegovy, under its umbrella.</p><h2 class="st-heading-2"><strong>FTC Flags Premerger Concerns</strong></h2><p>The U.S. Federal Trade Commission warned that Novo’s offer could breach the Hart-Scott-Rodino Act if completed without premerger review. In a Nov. 4 letter, the FTC said the structure of Novo’s bid, which grants substantial upfront payments before regulatory approval, could reduce Metsera’s independence and incentive to pursue its drug pipeline.</p><h2 class="st-heading-2"><strong>Stocktwits Bulls Cheer, Bears Question The Deal</strong></h2><p>On Stocktwits, retail sentiment for Novo Nordisk was ‘extremely bullish’ amid a 159% jump in 24-hour message volume.</p><figure class="image"><img style="aspect-ratio:964/138;" src="https://news.stocktwits-cdn.com/nvo_ss_jpg_016bd02a5d.webp" alt="nvo ss.jpg" width="964" height="138"><figcaption>NVO sentiment and message volume as of November 5 | Source: Stocktwits</figcaption></figure><p>One user suggested that better days could be close, urging others to “hold strong.”</p><p><stembedurl>https://stocktwits.com/RunGoodStreakAlive/message/635121830</stembedurl></p><p>Another user, however, questioned whether Novo’s management understood investor sentiment, noting that Pfizer’s stock tends to rise each time it appears closer to reclaiming the Metsera deal, suggesting that shareholders aren’t convinced by Novo’s acquisition push.</p><p><stembedurl>https://stocktwits.com/GreenHawkz/message/635102183</stembedurl></p><p><a href="https://stocktwits.com/symbol/NVO">Novo Nordisk’s U.S.-listed stock</a> has declined 43% so far in 2025.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Ozempic manufactured by Novo Nordisk packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on December 7, 2023. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Novo Nordisk Snaps 11-Day Losing Streak After Court Rejects Pfizer’s Challenge To $10B Metsera Deal

Delaware Chancery Judge Morgan Zurn ruled that Pfizer’s objections did not justify delaying Novo’s $10 billion acquisition of obesity-drug startup Metsera.

<ul class="summary-bullets"><li>Novo Nordisk cut its 2025 profit and sales forecasts as slower GLP-1 growth and pricing pressure hit margins.</li><li>Q3 sales rose 5% to 75 billion kroner, with Wegovy revenue up 18% but below expectations.</li><li>UBS said a potential $149-per-month U.S. pricing deal for obesity drugs could expand Medicare access but also weigh on Novo Nordisk’s global pricing power.</li></ul><p>Novo Nordisk’s new CEO, Mike Doustdar, cut the company’s profit forecast after slower Wegovy sales and rising competition in the obesity-drug market. The downgrade comes as the firm pursues a $10 billion bid for Metsera and, reportedly, nears a White House deal that could cap obesity-drug prices at $149 a month in exchange for Medicare coverage.</p><h2 class="st-heading-2"><strong>Earnings Review</strong></h2><p>Novo Nordisk, the maker of Wegovy and Ozempic, lowered its full-year guidance on Wednesday, signaling a rocky start for new CEO Mike Doustdar. The company now expects operating profit growth of 4%–7% in local currencies for 2025, down from an earlier 10%–16%, and sales growth of 8%–11%, below the previous 8%–14% range.</p><p>Doustdar attributed the cut to “lower growth expectations for our GLP-1 treatments,” adding that the company will accelerate efforts “to compete better in dynamic and increasingly competitive markets.”</p><p>Third-quarter sales rose 5 % to 75 billion Danish crowns ($11.7 billion). Wegovy sales climbed 18% to 20.35 billion Danish crowns, but missed expectations of 21.35 billion Danish crowns, as pricing pressure and rising competition from Eli Lilly’s Zepbound weighed on performance.</p><h2 class="st-heading-2"><strong>New CEO Faces Early Test</strong></h2><p>Doustdar, who took charge in August, faces one of Novo Nordisk’s toughest transitions in years. The company’s shares have dropped 43% in 2025, as pricing wars, U.S. policy headwinds, and management reshuffles have dented investor confidence in what was once Europe’s most valuable firm.</p><p>Novo Nordisk said its company-wide restructuring aims to streamline operations and reinvest for growth, with a renewed focus on obesity treatments.</p><h2 class="st-heading-2"><strong>Metsera Bid And Legal Battles</strong></h2><p>The Danish drugmaker’s revised $10 billion offer for U.S. obesity biotech Metsera has intensified its rivalry with Pfizer, which has filed two lawsuits alleging anticompetitive behavior.&nbsp;</p><p>Novo Nordisk dismissed the claims as “false and without merit.” Metsera said Novo’s latest proposal was “superior” to Pfizer’s, but the escalating bid raises investor concerns about cost discipline amid narrowing profit growth.</p><h2 class="st-heading-2"><strong>US Pricing Talks</strong></h2><p>Adding to the uncertainty, UBS said in a research note that Novo Nordisk and Eli Lilly’s supposed deal with the White House on obesity-drug pricing would cap prices at $149 per month for the lowest dose in exchange for Medicare coverage.</p><p>The investment bank described its stance as “mixed,” while Medicare inclusion could drive volume upside, the $149 price level represents a major discount versus global obesity-drug pricing. UBS, which rates Novo Nordisk shares as ‘Neutral’ with a 340 Danish crowns price target, said investors will watch whether the deal includes the Inflation Reduction Act’s Part D drug-price negotiation for semaglutide, and whether Novo has offered deep Wegovy discounts to preserve Ozempic pricing.</p><h2 class="st-heading-2"><strong>Investor Sentiment</strong></h2><p>Before the earnings announcement, Bourbon Capital&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/BourbonCap/status/1985846608320188641">noted in a post on X</a> that the company’s earnings yield and return on capital were considered "attractive," signaling confidence in Novo’s long-term profitability.</p><h2 class="st-heading-2"><strong>Stocktwits Users Debate Novo Nordisk’s Post-Earnings Dip</strong></h2><p>On Stocktwits, retail sentiment for Novo Nordisk was ‘extremely bullish’ amid ‘extremely high’ message volume.</p><figure class="image"><img style="aspect-ratio:966/139;" src="https://news.stocktwits-cdn.com/nvo_ss_jpg_fe9afe78a9.webp" alt="nvo ss.jpg" width="966" height="139"><figcaption>NVO sentiment and message volume as of November 4 | Source: Stocktwits</figcaption></figure><p>One user said approval of Novo Nordisk’s GLP-1 pill in the U.S., combined with its recent acquisitions, could “make this stock explode,” predicting that the post-earnings dip would be quickly bought once European markets opened.</p><p><stembedurl>https://stocktwits.com/GetRektDoggy/message/634975033</stembedurl></p><p>Another user said the results amounted to a “small miss as expected,” noting that guidance had merely narrowed and speculated&nbsp;on the market’s move ahead of the Trump deal.</p><p><stembedurl>https://stocktwits.com/NorthstarT1D/message/634973987</stembedurl></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Novo Nordisk Q3 earnings and revenue climbed by double-digit percentages.

Can Novo Nordisk’s ‘Attractive’ Fundamentals Outweigh Slowing Wegovy Sales And A $149 Price Cap?

Novo Nordisk cut its 2025 profit and sales forecasts as slower GLP-1 growth and pricing pressure hit margins.

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.

Metsera Inc.

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

MTSR
Metsera Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MTSR News

MTSRMetsera Inc